La Jolla Cancer Research Foundation

Sanford-burnham Medical Research Institute

The Burnham Institute

Sanford Burnham Prebys Medical Discovery Institute

Burnham Institute for Medical Research

University of California

Vascular Biosciences

Other

Kyungpook National University Industry-academic Cooperation Foundation

La Jolla Cancer Research Center

La Jolla Cancer Research Institute

The Burnam Institute

Lisata Therapeutics, Inc.

The University of Western Australia

Cepep III Ab

Erkki I Ruoslahti

Michael D Pierschbacher

Renata Pasqualini

Tambet Teesalu

Kazuki Sugahara

Kimmo Porkka

Douglas Hanahan

Pirjo Laakkonen

Lianglin Zhang

Jason A Hoffman

Erkki Koivunen

Yu Yamaguchi

Pablo Scodeller

David M Mann

Sven Christian

Masanobu Komatsu

Alex Morla

Sazid Hussain

Wayne A Border

Darren M Brown

Shweta Sharma

Aman Mann

Wadih Arap

Deidre A MacKenna

Guido Tarone

Kristiina Vuori

Venkata Ramana Kotamraju

Kurt R Gehlsen

Filippo G Giancotti

Bruce E Vogel

Jan Pilch

Shoukat Dedhar

Daniel Rajotte

Tero Järvinen

Markus Essler

Jih-Tung Pai

Michelle Matter

Yiwen Jan

Priya Prakash Karmali

William S Craig

In-San Kim

Byung-Heon Lee

Daniel G Mullen

Eva Engvall

James W Polarek

Lise Roth

Edward G Hayman

Aman Preet Singh Mann

Eva S Engvall

Michael T Longaker

Hongbo Pang

Harri Jarvelainen

David J Whitby

Jose Cardenas

Marianne P Petrica

Michael A Burg

William B Stallcup

Johanna A Joyce

Valentina Fogal

Gabriele Bergers

Lilach Agemy

Juliana Hamzah

Ralf Butzow

Dmitri Simberg

Ülo Langel

Lauri Paasonen

Hector R Biliran Jr

David Mann

Maarja Mäe

Helena Myrberg

Provided herein are novel cyclic peptides, their synthetic process, compositions, properties including stability and pharmacokinetic profiles, and applications for treating solid tumor cancers.

Pharmaceutical compositions comprising novel cyclic peptides

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Methods and compositions using peptides and proteins with c-terminal elements

Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3). Also disclosed are conjugates and compositions that onclude the peptides and/or peptidomimetics, methods for directing a moiety to tumor lymphatic vasculature, methods for imaging tumor lymphatic vasculature, methods for reducing or inhibiting tumor metastasis, methods for reducing the number of tumor lymphatic vessels, methods for treating cancer, methods for treating a disease or disorder associated with a gC1q/p32 receptor biological activity, methods for detecting the presence of a gC1q/p32 receptor, methods for detecting interactions between gC1q/p32 receptors and the presently disclosed conjugates and compositions, methods for delivering the presently disclosed conjugates and compositions to gC1q/p32 receptors, methods for assessing gC1q/p32 receptor levels in cells, methods for identifying subjects having diseases associated with gC1q/p32 receptor biological activities, and methods for screening for compounds that interact with gC1q/p32 receptors.

Targeted delivery system and methods of use therefor

Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.

Compositions that target tumor-associated macrophages and methods of use therefor

Disclosed are compositions and methods useful for targeting molecules to activated macrophages, such as tumor associated macrophages. The compositions and methods are based on peptide sequences, such as AMT peptides, that home to activated macrophages. The disclosed homing to activated macrophages is useful for delivering therapeutic and detectable agents to cells and tissues where immune system effects or inflammation are occurring.

Tumor associated monocyte/macrophage binding peptide and methods of use thereof

Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.

Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same

The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described here are unique in the field and can be expected to advance understanding on early neurodegenerative changes associated with AD and improve the therapeutic outcomes by early detection and intervention in AD. Further, the invention provides antibodies that can be used to treat AD.

Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof

Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3). Also disclosed are conjugates and compositions that include the peptides and/or peptidomimetics, methods for directing a moiety to tumor lymphatic vasculature, methods for imaging tumor lymphatic vasculature, methods for reducing or inhibiting tumor metastasis, methods for reducing the number of tumor lymphatic vessels, methods for treating cancer, methods for treating a disease or disorder associated with a gC1q/p32 receptor biological activity, methods for detecting the presence of a gC1q/p32 receptor, methods for detecting interactions between gC1q/p32 receptors and the presently disclosed conjugates and compositions, methods for delivering the presently disclosed conjugates and compositions to gC1q/p32 receptors, methods for assessing gC1q/p32 receptor levels in cells, methods for identifying subjects having diseases associated with gC1q/p32 receptor biological activities, and methods for screening for compounds that interact with gC1q/p32 receptors.

Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.

Compounds and compositions for targeting brain injuries and methods of use thereof

Disclosed are methods and compositions for treating traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Significantly, the peptide alone produces therapeutic effect and so can be used in the absence of any other therapeutic compound.

Compositions and methods for treating nervous system injuries

Methods and compositions related to peptides and proteins with C-terminal elements

Methods and compositions using peptides and proteins with C-terminal elements

Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Erkki I Ruoslahti